Page 3 - Affairs Regulatory News Today : Breaking News, Live Updates & Top Stories | Vimarsana

DCGI approves AstraZeneca’s eosinophilic asthma drug DCGI approves AstraZeneca’s eosinophilic asthma drug 22 December 2020 | News Source credit: AstraZeneca AstraZeneca India, a leading science-led biopharmaceutical company, has received marketing authorisation from Drugs Controller General of India (DCGI) for - use of the original research medicine, Fasenra™ (Benralizumab solution for injection in a single dose prefilled syringe30 mg/ml subcutaneous administration only) in patients with severe asthma (eosinophilic asthma). Benralizumab (Fasenra™) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients. Fasenra™ is an add-on maintenance treatment for patients with severe eosinophilic asthma. It is designed to target cells in the body called eosinophils, which are a key cause of the eosinophilic subtype of asthma. Fasenra™is not an inhaler or a steroid and is administered once in 8 weeks under the skin

Benralizumab fasenraGagandeep singh bediAffairs regulatoryAstrazeneca indiaDrugs controller generalSingh bediManaging directorAnil kukrejaVice presidentMedical affairsககந்டீப் சிங் பேடிவாழ்க்கைத்தொழில்கள் ஒழுங்குமுறைமருந்துகள் கட்டுப்படுத்தி ஜநரல்சிங் பேடிநிர்வகித்தல் இயக்குனர்அனில் கூகிறெஜா